title: Effects of telmisartan and pioglitazone on high fructose induced metabolic syndrome in rats.
abstract: Metabolic syndrome (MS) is a cluster of hypertension, insulin resistance, dyslipidaemia, and hyperuricemia. This study was designed to assess the effect of telmisartan and pioglitazone on high fructose induced MS. Thirty-five male albino rats were classified into 5 groups: A, normal diet; B, high-fructose diet (HFD) subdivided into B1 (HFD only), B2 (telmisartan, 5 mg/kg), B3 (pioglitazone, 10 mg/kg), and B4 (telmisartan + pioglitazone). Administration of the drugs was started after the rats had been on HFD for 4 weeks and continued for 4 weeks. Body mass (BM), blood pressure (BP), uric acid (UA), total cholesterol, triglycerides (TG), high-density lipoprotein (HDL-c), low-density lipoprotein (LDL-c), blood urea nitrogen (BUN), creatinine, and nitric oxide (NO) were measured and the levels of fasting glucose and fasting insulin were estimated. Compared with group B1, telmisartan treatment significantly decreased BP, BM, serum glucose, insulin, UA, urea, cholesterol, TGA, and LDL and significantly increased HDL, whereas pioglitazone treatment significantly decreased BP, serum glucose, insulin, UA, urea, creatinine, cholesterol, TGA, and LDL and significantly increased HDL. Co-administration of pioglitazone + telmisartan significantly decreased insulin, urea, and creatinine compared with telmisartan alone. Combined telmisartan + pioglitazone allowed better control of BP, hyperglycaemia, insulin resistance, and the amelioration of BM increase that may be associated with pioglitazone treatment.
authors.affiliation: a Pharmacology Department, Beni Suef University, Beni Suef, Egypt.
authors.forename: Mary Girgis
authors.initials: MG
authors.lastname: Shahataa
authors.affiliation: a Pharmacology Department, Beni Suef University, Beni Suef, Egypt.|b Pharmacology Department, Faculty of Medicine, Al Jouf University, Al Jouf, Saudia Arabia.
authors.forename: Gomaa
authors.initials: G
authors.lastname: Mostafa-Hedeab
authors.affiliation: c Pharmacology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: Esam Fouaad
authors.initials: EF
authors.lastname: Ali
authors.affiliation: d Pathology Department, Faculty of Veterinary Medicine, Beni Suef University, Egypt.
authors.forename: Emad Ahmed
authors.initials: EA
authors.lastname: Mahdi
authors.affiliation: c Pharmacology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: Fatma Abd Elhaleem
authors.initials: FA
authors.lastname: Mahmoud
mesh_terms: D000818:Animals; D001562:Benzimidazoles / Q000008:administration & dosage*; D001565:Benzoates / Q000008:administration & dosage*; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D004359:Drug Therapy, Combination; D005632:Fructose / Q000633:toxicity*; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007333:Insulin Resistance / Q000502:physiology; D008297:Male; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000188:drug therapy* / Q000378:metabolism; D000077205:Pioglitazone; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077333:Telmisartan; D045162:Thiazolidinediones / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D001562:Benzimidazoles; D001565:Benzoates; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D005632:Fructose; D000077333:Telmisartan; D000077205:Pioglitazone
keywords: acide urique; blood pressure; body mass; dyslipidaemia; dyslipidémie; insulin resistance; metabolic syndrome; pioglitazone; poids corporel; résistance à l’insuline; syndrome métabolique; telmisartan; tension artérielle; uric acid